Intelligence for what moves markets next.
Forward Matter turns complex market signals into quantitative, rules-based investment decisions. Quantitative trading and portfolio intelligence software for wealth advisers, asset managers and funds.
Thousands of events. Automated decision making.
Matter Engine continuously interprets distinct information environments, then identifies the relationships that become material to markets and portfolios.
Healthcare events
Clinical milestones, regulatory decisions, patents and commercial developments.
Fundamental change
Earnings, guidance, ownership, competitive moves and capital allocation.
Price and flow
Liquidity, volatility, positioning and institutional market behaviour.
Matter Engine
Relationship mapping, probability modelling and systematic decision infrastructure. New technology, now in beta.
Architecture and signal logic remain proprietaryRanked opportunities
Expected impact, timing, confidence and risk presented for investment review.
Risk aware allocation
Position sizing and exposure shaped by institutional mandates and constraints.
Governed action
Automated execution inside the rails, with monitoring and oversight.
Predictive models
One calibrated probability for each event that already has a date on it, read only from what was published before it resolves.
Reads as it posts
Each document is read and time-stamped as it is published, and orders are drafted before the open.
Risk-aware sizing
Every position is sized to its worst case and checked against fixed limits before an order is sent.
Always-on monitoring
Software watches every source on its schedule and flags what changed. People approve the rules it runs to.
Catalysts arrive on schedule. We model every state they can resolve into.
A dated catalyst is one input among thousands. The engine weighs each possible outcome against the sentiment, flow and conditions around it, and revises as evidence lands.
One platform. Specialist capabilities.
Research, modelling and portfolio tools designed to work across the investment process.
Matter Intelligence
Research, signal detection and forecasting.
Matter Engine
Modelling and automated strategy infrastructure.
Matter Portfolio
Portfolio construction and risk management.
Matter Health
Healthcare and life sciences intelligence.
Matter Markets
Emerging market and macro intelligence.
Matter API
Institutional data and software integration.
Matter Terminal
A professional interface for analysts and portfolio managers.
The Foundation
A rules-based stock picker that screens every healthcare company before it is bought.
Nowcaster
Estimates a company's quarterly sales before it reports them.
Prescription Reader
Turns weekly prescription data into an early read on a medicine's sales.
Catalyst
Reads regulatory documents ahead of dated decisions, starting with the FDA Reader.
Momentum
Reads each share's trend against its market, and leans with it.
Policy Reader
Follows the bills, orders and rules that move drug prices, from first bill to law.
One molecule, every catalyst dated in advance.
Tirzepatide's approvals, indications and earnings dates were all published before they happened. Lilly's shares went from an average of $152.16 across November and December 2020 to $1,149.36 on 4 September 2026, and the company passed a trillion dollars of market value on 21 November 2025.
$152May 2022
MounjaroNov 2023
$587Sep 2026
$1,149
Figures as at 4 September 2026. The four points are period markers, not a daily price path.
More of the future is knowable than the market assumes.
A great deal of what will move a market is already documented, dated and discussed in public. We exist to make that readable, so a decision rests on evidence rather than instinct. Talk to us about how that could extend your firm, platform or fund.